Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:PIRS's Cash-to-Debt is ranked higher than
73% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. NAS:PIRS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:PIRS' s Cash-to-Debt Range Over the Past 10 Years
Min: 14.54  Med: No Debt Max: No Debt
Current: No Debt
14.54
No Debt
Equity-to-Asset 0.34
NAS:PIRS's Equity-to-Asset is ranked lower than
85% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. NAS:PIRS: 0.34 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:PIRS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.05  Med: 0.72 Max: 0.93
Current: 0.34
0.05
0.93
Interest Coverage No Debt
NAS:PIRS's Interest Coverage is ranked higher than
67% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:PIRS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:PIRS' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 6
Altman Z-Score: 1.37
Beneish M-Score: 0.51
WACC vs ROIC
11.39%
11.77%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -23.93
NAS:PIRS's Operating Margin % is ranked higher than
57% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. NAS:PIRS: -23.93 )
Ranked among companies with meaningful Operating Margin % only.
NAS:PIRS' s Operating Margin % Range Over the Past 10 Years
Min: -466.61  Med: -390.31 Max: -23.93
Current: -23.93
-466.61
-23.93
Net Margin % -22.38
NAS:PIRS's Net Margin % is ranked higher than
56% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. NAS:PIRS: -22.38 )
Ranked among companies with meaningful Net Margin % only.
NAS:PIRS' s Net Margin % Range Over the Past 10 Years
Min: -479.5  Med: -391 Max: -22.38
Current: -22.38
-479.5
-22.38
ROE % -32.28
NAS:PIRS's ROE % is ranked lower than
74% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. NAS:PIRS: -32.28 )
Ranked among companies with meaningful ROE % only.
NAS:PIRS' s ROE % Range Over the Past 10 Years
Min: -213.33  Med: -93.17 Max: -32.28
Current: -32.28
-213.33
-32.28
ROA % -6.59
NAS:PIRS's ROA % is ranked higher than
65% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. NAS:PIRS: -6.59 )
Ranked among companies with meaningful ROA % only.
NAS:PIRS' s ROA % Range Over the Past 10 Years
Min: -200  Med: -74.43 Max: -6.59
Current: -6.59
-200
-6.59
ROC (Joel Greenblatt) % -125.22
NAS:PIRS's ROC (Joel Greenblatt) % is ranked higher than
61% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. NAS:PIRS: -125.22 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:PIRS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1265  Med: -1028.19 Max: -125.22
Current: -125.22
-1265
-125.22
3-Year EBITDA Growth Rate -586.80
NAS:PIRS's 3-Year EBITDA Growth Rate is ranked lower than
100% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. NAS:PIRS: -586.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:PIRS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -293.4 Max: -586.8
Current: -586.8
GuruFocus has detected 1 Warning Sign with Pieris Pharmaceuticals Inc NAS:PIRS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:PIRS's 30-Y Financials

Financials (Next Earnings Date: 2018-11-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

PIRS Guru Trades in Q3 2017

Jim Simons 397,100 sh (+242.62%)
» More
Q4 2017

PIRS Guru Trades in Q4 2017

Chuck Royce 752 sh (New)
Jim Simons 650,100 sh (+63.71%)
» More
Q1 2018

PIRS Guru Trades in Q1 2018

Joel Greenblatt 36,620 sh (New)
Jim Simons 1,529,800 sh (+135.32%)
Chuck Royce 557 sh (-25.93%)
» More
Q2 2018

PIRS Guru Trades in Q2 2018

Chuck Royce 1,778 sh (+219.21%)
Joel Greenblatt Sold Out
Jim Simons 1,522,600 sh (-0.47%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:PIRS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2018-06-30 Sold Out $5.03 - $6.88 $ 5.09-14%0
Joel Greenblatt 2018-03-31 New Buy$6.8 - $9.45 $ 5.09-34%36,620
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Pieris Pharmaceuticals Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:LSE:ARIX, XTER:MDG1, NAS:SNNA, NAS:IDRA, WAR:CLN, NAS:CARA, SZSE:002868, OSTO:ONCO, XPAR:IPH, XSWX:SKIN, XKRX:019175, NAS:ADVM, NAS:NITE, NAS:SYRS, NAS:CLSD, SHSE:603229, NAS:ALBO, TSE:4563, NAS:MRSN, TSXV:EMH » details
Traded in other countries:PI6.Germany,
Headquarter Location:USA
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in discovering and developing Anticalin class of biotherapeutics for patients with diseases in which there is high unmet medical needs.

Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, PRS-343 and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm is functioned through the region of US.

Top Ranked Articles about Pieris Pharmaceuticals Inc

Pieris Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Pieris Pharmaceuticals to Present at the 2018 Wedbush PacGrow Healthcare Conference
Pieris Pharmaceuticals to Host Second Quarter 2018 Investor Call and Corporate Update on August 9, 2018
Pieris Pharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference
Pieris Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
Pieris Pharmaceuticals to Present at 43rd Annual Deutsche Bank Health Care Conference
Investor Expectations to Drive Momentum within Blackbaud, Pieris Pharmaceuticals, Sarepta Therapeutics, Cambrex, Stoneridge, and First Interstate BancSystem — Discovering Underlying Factors of Influence
Largest Insider Trades of the Week Insiders keep buying Sprint Corp
The GuruFocus All-in-One Screener can be used to find insider trades from the past week. Under the Insiders tab, change the settings for All Insider Buying to “$200,000+,” the duration to “January 2018” and All Insider Sales to “$5,000,000+.” Read more...
Consolidated Research: 2018 Summary Expectations for Pieris Pharmaceuticals, Cincinnati Bell, FormFactor, Belden, Watts Water Technologies, and Anixter International — Fundamental Analysis, Key Performance Indications

Ratios

vs
industry
vs
history
Price-to-Owner-Earnings 5.83
PIRS's Price-to-Owner-Earnings is ranked higher than
90% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 34.35 vs. PIRS: 5.83 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PIRS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.79  Med: 6.37 Max: 8.27
Current: 5.83
5.79
8.27
PB Ratio 4.96
PIRS's PB Ratio is ranked lower than
64% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. PIRS: 4.96 )
Ranked among companies with meaningful PB Ratio only.
PIRS' s PB Ratio Range Over the Past 10 Years
Min: 1.86  Med: 5.58 Max: 63.11
Current: 4.96
1.86
63.11
PS Ratio 6.41
PIRS's PS Ratio is ranked higher than
56% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PIRS: 6.41 )
Ranked among companies with meaningful PS Ratio only.
PIRS' s PS Ratio Range Over the Past 10 Years
Min: 6.37  Med: 19.28 Max: 535.71
Current: 6.41
6.37
535.71
Price-to-Free-Cash-Flow 4.61
PIRS's Price-to-Free-Cash-Flow is ranked higher than
96% of the 152 Companies
in the Global Biotechnology industry.

( Industry Median: 37.07 vs. PIRS: 4.61 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PIRS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.58  Med: 6.17 Max: 32.57
Current: 4.61
4.58
32.57
Price-to-Operating-Cash-Flow 4.42
PIRS's Price-to-Operating-Cash-Flow is ranked higher than
95% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 29.99 vs. PIRS: 4.42 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PIRS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.39  Med: 5.99 Max: 27.89
Current: 4.42
4.39
27.89
EV-to-EBIT -8.46
PIRS's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. PIRS: -8.46 )
Ranked among companies with meaningful EV-to-EBIT only.
PIRS' s EV-to-EBIT Range Over the Past 10 Years
Min: -26  Med: -5 Max: -1.3
Current: -8.46
-26
-1.3
EV-to-EBITDA -8.66
PIRS's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. PIRS: -8.66 )
Ranked among companies with meaningful EV-to-EBITDA only.
PIRS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -26.5  Med: -5.1 Max: -1.3
Current: -8.66
-26.5
-1.3
EV-to-Revenue 4.43
PIRS's EV-to-Revenue is ranked higher than
72% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. PIRS: 4.43 )
Ranked among companies with meaningful EV-to-Revenue only.
PIRS' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.2  Med: 11.5 Max: 443.5
Current: 4.43
3.2
443.5
Current Ratio 2.99
PIRS's Current Ratio is ranked lower than
63% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. PIRS: 2.99 )
Ranked among companies with meaningful Current Ratio only.
PIRS' s Current Ratio Range Over the Past 10 Years
Min: 1.96  Med: 4.66 Max: 15.23
Current: 2.99
1.96
15.23
Quick Ratio 2.99
PIRS's Quick Ratio is ranked lower than
61% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. PIRS: 2.99 )
Ranked among companies with meaningful Quick Ratio only.
PIRS' s Quick Ratio Range Over the Past 10 Years
Min: 1.96  Med: 4.66 Max: 15.23
Current: 2.99
1.96
15.23
Days Sales Outstanding 24.63
PIRS's Days Sales Outstanding is ranked higher than
69% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. PIRS: 24.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
PIRS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.57  Med: 114.04 Max: 224.5
Current: 24.63
3.57
224.5

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -48.10
PIRS's 3-Year Average Share Buyback Ratio is ranked lower than
84% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. PIRS: -48.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PIRS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -55.9  Med: -52 Max: -48.1
Current: -48.1
-55.9
-48.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 6.21
PIRS's Price-to-Net-Cash is ranked lower than
56% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. PIRS: 6.21 )
Ranked among companies with meaningful Price-to-Net-Cash only.
PIRS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0  Med: 3.58 Max: 11.96
Current: 6.21
0
11.96
Price-to-Net-Current-Asset-Value 5.53
PIRS's Price-to-Net-Current-Asset-Value is ranked lower than
53% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. PIRS: 5.53 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PIRS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 4.81 Max: 294
Current: 5.53
0
294
Price-to-Tangible-Book 4.94
PIRS's Price-to-Tangible-Book is ranked lower than
56% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. PIRS: 4.94 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PIRS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.86  Med: 5.22 Max: 57.09
Current: 4.94
1.86
57.09
Price-to-Median-PS-Value 0.33
PIRS's Price-to-Median-PS-Value is ranked higher than
79% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. PIRS: 0.33 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PIRS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 0.98 Max: 22.86
Current: 0.33
0
22.86
Earnings Yield (Greenblatt) % -11.86
PIRS's Earnings Yield (Greenblatt) % is ranked lower than
55% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. PIRS: -11.86 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PIRS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -79.7  Med: -20.1 Max: -3.8
Current: -11.86
-79.7
-3.8

More Statistics

Revenue (TTM) (Mil) $37.92
EPS (TTM) $ -0.15
Beta1.41
Volatility47.83%
52-Week Range $4.43 - 9.75
Shares Outstanding (Mil)54.03

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 28 28 32
EBIT (Mil $) -26 -35 -47
EBITDA (Mil $) -26 -35 -47
EPS ($) -0.51 -0.64 -0.70
EPS without NRI ($) -0.51 -0.64 -0.70
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAN
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}